
Sign up to save your podcasts
Or


Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios:
1. Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and ferritin levels, exploring treatment options including the safety and efficacy of IV iron versus oral iron.
Throughout the episode, we emphasized the significance of a comprehensive iron panel and the clinical context in diagnosing and managing these conditions. Dr. Beltrami shared valuable insights on the use of erythropoietin-stimulating agents in chronic kidney disease and the potential risks associated with their use.
Tune in for an informative discussion packed with practical insights for healthcare professionals dealing with iron-related disorders!
Follow us on social media:
Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. We are the Oncology Brothers!
#Anemia #IronDeficiency #Hemochromatosis #IronOverload #Hematology #Ferritin #OncologyBrothers
By Oncology Brothers4.8
4040 ratings
Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios:
1. Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and ferritin levels, exploring treatment options including the safety and efficacy of IV iron versus oral iron.
Throughout the episode, we emphasized the significance of a comprehensive iron panel and the clinical context in diagnosing and managing these conditions. Dr. Beltrami shared valuable insights on the use of erythropoietin-stimulating agents in chronic kidney disease and the potential risks associated with their use.
Tune in for an informative discussion packed with practical insights for healthcare professionals dealing with iron-related disorders!
Follow us on social media:
Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. We are the Oncology Brothers!
#Anemia #IronDeficiency #Hemochromatosis #IronOverload #Hematology #Ferritin #OncologyBrothers

324 Listeners

40 Listeners

120 Listeners

58 Listeners

297 Listeners

2,439 Listeners

3,357 Listeners

1,142 Listeners

204 Listeners

187 Listeners

43 Listeners

22 Listeners

189 Listeners

59 Listeners

193 Listeners